(19)
(11) EP 3 118 211 A8

(12) CORRECTED EUROPEAN PATENT APPLICATION
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)

(48) Corrigendum issued on:
06.09.2017 Bulletin 2017/36

(43) Date of publication:
18.01.2017 Bulletin 2017/03

(21) Application number: 15761359.7

(22) Date of filing: 27.02.2015
(51) International Patent Classification (IPC): 
C07K 5/06(2006.01)
A61K 38/05(2006.01)
A61P 31/14(2006.01)
A61P 31/04(2006.01)
A61P 11/00(2006.01)
A61P 1/04(2006.01)
C07K 5/037(2006.01)
A61P 31/12(2006.01)
A61P 31/20(2006.01)
A61P 27/02(2006.01)
A61P 11/06(2006.01)
A61P 1/16(2006.01)
(86) International application number:
PCT/RU2015/000121
(87) International publication number:
WO 2015/137846 (17.09.2015 Gazette 2015/37)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 12.03.2014 RU 2014109441

(71) Applicant: Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises"
Moscow 117571 (RU)

(72) Inventors:
  • NEBOLSIN, Vladimir Evgenievich
    Istrinsky r-n Moskovskaya obl. 143581 (RU)
  • KROMOVA, Tatyana Alexandrovna
    Kaluga 248010 (RU)

(74) Representative: Hoffmann Eitle 
Patent- und Rechtsanwälte PartmbB Arabellastraße 30
81925 München
81925 München (DE)

   


(54) AMIDE COMPOUNDS AND METHODS FOR THE PRODUCTION AND USE THEREOF


(57) The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.